Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Delivery
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28679
Licensor hereby grant to XTL an exclusive, world-wide, perpetual, irrevocable, license to develop, have developed, manufacture, have manufactured, produce, have produced, use, provide, market, offer for sale, sell, have sold, export and import Licensed Products (the 'License').
The SAM-101 is a drug (combination drug to treat mental disorders focusing on schizophrenia).
COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS – The present invention relates to the use of combinations of an antipsychotic drug and a tetracycline in the treatment of psychiatric disorders, particularly schizophrenia. The invention describes the composition, methods of use, type of formulations, methods of administration, and a kit for the use of said combinations. The invention also provides methods for a combined therapy for treatment of psychiatric disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline. The invention also provides a method for delaying or preventing the onset of schizophrenia.
US Prov.
60/852646
19/Oct/2006
USA
12/446444
18/Oct/2007
The Licensee will conduct clinical trials, develop, register, market, distribute and sell the drugs arising from the developed technology, regardless of a specific disease.
IPSCIO Record ID: 291187
– a license under the Licensor Technology to research, develop, import, use, sell, have sold and offer for sale the Product in the Field in the Territory, with such license being exclusive under the Licensor Product Patents and Licensor Know-How and non-exclusive under the Licensor Background Patents.
– a worldwide license under the Licensor Technology to manufacture and have manufactured the Product for use and sale in the Field in the Territory, with such license being co-exclusive with Licensor under the Licensor Product Patents and Licensor Know-How and non-exclusive under the Licensor Background Patents;
– a non-exclusive license solely to conduct clinical and non-clinical development activities with respect to .the Product outside the Territory, solely for the purpose of researching, developing, importing, using, selling, having sold and offering for sale the Product in the Field in the Territory;
For the Trademark and Copyright License, Licensor grants and causes its Affiliates to grant to Licensee, under the Licensor Trademarks and Copyrights an exclusive license to research, develop, manufacture, have manufactured, import, use, sell, have sold and offer for sale Product in the Field in the Territory and a non-exclusive license solely to conduct clinical and non-clinical development activities with respect to the Product outside the Territory, solely for the purpose of researching, developing, importing, using, selling having sold and offering for sale the Product in the Field in the Territory.
Device shall mean any hand-held, single-use, fixed-dosage device for the administration of API( s) which device relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of APl(s) through deep lung inhalation, which device is known as or based on, but may or may not be referred to, as the Staccato® system.
Loxapine shall mean the compound or any metabolite, salt, polymorphic form, free base form or prodrug form of such compound. Loxapine is for the treatment of psychiatric and/or neurological indications and the symptoms associated therewith, including the rapid treatment of agitation associated with schizophrenia or bipolar disorder. The Product shall be sold in the Territory under the Trademark Adasuveâ„¢
The products will display both trademarks Adasuve and Staccato.
Field shall mean the prevention or treatment of any psychiatric and/or neurological indication and the symptoms associated with these indications.
IPSCIO Record ID: 146229
